Milestone Pharmaceuticals Inc. (MIST) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
MIST currently has 118M outstanding shares. with significant dilution risk as 126M authorized shares could dilute existing holders by 107.2%. The company has significantly diluted shareholders by 101.47% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
S-3 filing: The company is conducting an at-the-market offering of common shares with an aggregate offering price of up to $100,000,000. |
120M | 130M |
| May 13, 2026 |
10-Q filing | 124.5M shares outstanding |
120M | 120M |
| Mar 20, 2026 |
10-K filing | 106.2M shares outstanding |
110M | 140M |
| Nov 12, 2025 |
10-Q filing | 85.2M shares outstanding |
85M | 160M |
| Aug 12, 2025 |
10-Q filing | 85.0M shares outstanding |
85M | 160M |
| May 14, 2025 |
10-Q filing | 53.5M shares outstanding |
53M | 190M |
| Mar 13, 2025 |
10-K filing | 53.4M shares outstanding |
53M | 190M |
| Nov 12, 2024 |
10-Q filing | 53.3M shares outstanding |
53M | 190M |
| Nov 12, 2024 |
S-3 filing: The filing is for a shelf registration of common shares, preferred shares, debt securities, and warrants with a total offering amount of $250,000,000. |
53M | 190M |
| Aug 08, 2024 |
10-Q filing | 53.3M shares outstanding |
53M | 62M |
| May 13, 2024 |
10-Q filing | 33.5M shares outstanding |
33M | 82M |
| Mar 21, 2024 |
10-K filing | 33.5M shares outstanding |
33M | 82M |
| Nov 13, 2023 |
10-Q filing | 34.3M shares outstanding |
34M | 81M |
| Aug 10, 2023 |
10-Q filing | 34.3M shares outstanding |
34M | 81M |
| May 15, 2023 |
S-3 filing: This S-3 filing relates to the proposed offering and resale by selling stockholders of up to 13,888,850 common shares of Milestone Pharmaceuticals Inc. |
33M | 82M |
| May 11, 2023 |
10-Q filing | 33.3M shares outstanding |
33M | 68M |
| Mar 29, 2023 |
10-K filing | 34.3M shares outstanding |
34M | 67M |
| Mar 27, 2023 |
8-K filing: Milestone Pharmaceuticals Inc. exchanged 1,059,000 common shares for pre-funded warrants to purchase 1,059,000 common shares with RTW Investments. |
30M | 71M |
| Nov 10, 2022 |
10-Q filing | 30.4M shares outstanding |
30M | 71M |
| Aug 10, 2022 |
10-Q filing | 30.0M shares outstanding |
30M | 71M |
| May 12, 2022 |
10-Q filing | 29.9M shares outstanding |
30M | 71M |
| Mar 24, 2022 |
10-K filing | 29.9M shares outstanding |
30M | 71M |
| Feb 16, 2022 |
8-K filing: Milestone Pharmaceuticals, Inc. granted an inducement award in the form of an option to purchase 330,000 of the Company's common shares to David Bharucha in connection with his appointment as the Company's Chief Medical Officer. |
30M | 71M |
| Nov 12, 2021 |
10-Q filing | 29.9M shares outstanding |
30M | 71M |
| Nov 12, 2021 |
S-3 filing: The filing is an S-3 registration statement for Milestone Pharmaceuticals Inc., covering the potential offering and sale of up to $250,000,000 of any combination of common shares, preferred shares, debt securities, and warrants, with specific terms to be provided in prospectus supplements. |
30M | 71M |
| Oct 28, 2021 |
S-3/A filing: This S-3/A filing registers 910,746 common shares issuable upon exercise of pre-funded warrants for resale by selling shareholders. |
30M | 27M |
| Aug 11, 2021 |
10-Q filing | 29.8M shares outstanding |
30M | 27M |
| Jun 25, 2021 |
S-3 filing: The filing relates to the offer and resale of up to 910,746 common shares issuable upon exercise of pre-funded warrants by selling shareholders. |
30M | 27M |
| May 17, 2021 |
10-Q filing | 29.8M shares outstanding |
30M | 26M |
| Mar 29, 2021 |
10-K filing | 29.8M shares outstanding |
30M | 26M |
| Nov 13, 2020 |
10-Q filing | 29.8M shares outstanding |
30M | 26M |
| Aug 20, 2020 |
S-3 filing: The filing registers 6,655,131 common shares for resale by selling shareholders, issuable upon exercise of pre-funded warrants. |
25M | 31M |
| Aug 12, 2020 |
10-Q filing | 24.7M shares outstanding |
25M | 24M |
| Jun 19, 2020 |
S-3 filing: Milestone Pharmaceuticals Inc. is filing a registration statement on Form S-3 to register an indeterminate number of common shares and preferred shares, such indeterminate principal amount of debt securities and such indeterminate number of warrants to purchase common shares, preferred shares or debt securities as shall have an aggregate initial offering price not to exceed $100,000,000. |
25M | 25M |
| May 14, 2020 |
10-Q filing | 24.6M shares outstanding |
25M | 0 |
| Mar 06, 2020 |
10-K filing | 24.6M shares outstanding |
25M | 0 |